CHARLOTTE NELSON: Open Payments
NPI 1073650628 · WASILLA, AK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$842 in 30 payments from 14 companies in 2025. Trend: 2023 $1,625 · 2024 $1,281 · 2025 $842
Food & beverage: $842
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 4 | $172 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $86 |
| ABBVIE INC. | 4 | $86 |
| GENZYME CORPORATION | 2 | $69 |
| EMD Serono, Inc. | 2 | $65 |
| SK Life Science, Inc. | 2 | $64 |
| Neurelis, Inc. | 3 | $58 |
| Neurocrine BioSciences, Inc. | 2 | $57 |
| Alexion Pharmaceuticals, Inc. | 2 | $46 |
| Novartis Pharmaceuticals Corporation | 2 | $43 |
Products named: Fintepla, HYQVIA, UBRELVY, VALTOCO, INGREZZA, KESIMPTA, ZEPOSIA, AJOVY.
Industry payments across AK — which companies pay providers there.
